[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Article
Nov 2011

An Internally Controlled, Double-blind Comparison of the Efficacy of OnabotulinumtoxinA and AbobotulinumtoxinA

Author Affiliations

Author Affiliations: The Maas Clinic, San Francisco, California (Drs Nettar, Yu, Bapna, and Maas); and Departments of Otolaryngology–Head and Neck Surgery (Drs Nettar, Yu, Bapna, and Maas) and Biostatistics and Medicine (Dr Boscardin), University of California, San Francisco.

Arch Facial Plast Surg. 2011;13(6):380-386. doi:10.1001/archfacial.2011.37

Objective To compare 2 commercially available botulinum neuromodulators in a randomized, double-blind, split-face study.

Methods Ninety patients were treated with 10 U of onabotulinumtoxinA and 30 U of abobotulinumtoxinA for the treatment of lateral orbital rhytids. Patients were assessed live with a validated 5-point photographic scale prior to treatment and at 30 days. Patients were also photographed at each visit.

Results AbobotulinumtoxinA demonstrated a statistically significant advantage compared with onabotulinumtoxinA in the treatment of lateral orbital rhytids at maximal contraction, as evaluated independently by the investigator ( = .01) and patient ( = .03). AbobotulinumtoxinA was also favored by the patient over onabotulinumtoxinA 67% of the time. While abobotulinumtoxinA seemed to treat lateral orbital rhytids better at rest, as evidenced by the data and photographs, this difference was not statistically significant ( = .42).

Conclusions AbobotulinumtoxinA offers superior efficacy in the treatment of lateral orbital rhytids compared with onabotulinumtoxinA. Further studies are needed to compare the 2 products in different muscle groups and for other indications.